Clinical Trials تتوفر أدناه التجارب السريرية الحالية.550 الدراسات في Cancer (الدراسات المفتوحة فقط). تصفية قائمة الدراسات هذه حسب الموقع، والحالة والمزيد. Bladder Bank (a Prospective Banking Study) Rochester, Minn. The purpose of this study is to establish samples (blood and urine) to support the development of non-invasive tests for early detection of bladder cancer Human Blood and Tissues Repository for Neuroscience Research Jacksonville, Fla. The purpose of this study is to collect adult human blood, cerebrospinal fluid, brain, and spine tissues/fluids at time of surgery in order to conduct future studies of the cellular mechanisms of tissue invasion utilized by brain and spine tumors of the central nervous system (CNS). Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the safety and tolerability of OBT076, and to define the maximum tolerated dose (MTD) and/or the RP2D of OBT076. Recognition by Metabolomic Analysis of Serum of Hepatocellular Carcinoma Rochester, Minn. The purpose of this study is to validate an NMR-based (Nuclear magnetic resonance) serum metabolite constellation for detection of early Hepatocellular carcinoma (HCC) lesions in liver cirrhosis. MRD Guided, Fixed Duration Therapy With Loxo-305 and Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia Rochester, Minn. The purpose of this study is to determine if a new drug combination, pirtobrutinib and venetoclax, will help Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) cancer, as well as learn more about the side effects of this drug combination. Everyone in this study will receive pirtobrutinib and venetoclax. Venetoclax is U.S. Food and Drug Administration (FDA) approved for the treatment of CLL and SLL. Pirtobrutinib is currently being studied in patients with CLL but it is not FDA approved yet. This drug combination is still experimental and is not approved by the FDA. Discontinuation of pirtobrutinib and venetoclax based on minimal residual disease (MRD) results is also investigational. However, the FDA has allowed the use of this drug combination in this research study. Patient Survey of Molecular Breast Imaging Rochester, Minn. The purpose of this study is to gather qualitative information about patient comfort during MBI examinations. The primary aim is to assess patient comfort during MBI, relative to comfort during a mammogram. We also wish to identify factors that contribute to discomfort and patients’ willingness to have MBI in the future. Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC Rochester, Minn. The main purpose of the study is to evaluate safety and effectiveness of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC. Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer and Cervical Cancer: a Phase II Clinical Study Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. Hematology Electronic Consultations (e-Consults) the Mayo Clinic Experience Jacksonville, Fla. The purpose of this study is to evaluate hematology e-consults to determine their specific use, time to completion, advantages and disadvantages, perceptions from primary care physicians and specialists and economic impact. A Study of Sonidegib and Pembrolizumab in Advanced Solid Tumors Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the maximum tolerated dose (MTD) of sonidegib in combination with pembrolizumab in participants with advanced solid tumors as part of the dose escalation phase, and to estimate the response rate of sonidegib in combination with pembrolizumab in participants with NSCLC or pancreas cancer as part of the expansion cohort based on RECIST criteria. التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 1515 توجّه للصفحة 1616 توجّه للصفحة 1717 توجّه للصفحة 1818 توجّه للصفحة 1919 التاليالصفحة التالية المتخصصون في المجالات الطبية Cancer clinical-trials